Phase 1 clinical study of BLD-2184 in healthy volunteers
Latest Information Update: 12 Oct 2021
At a glance
- Drugs BLD-2184 (Primary)
- Indications Neurodegenerative disorders
- Focus Adverse reactions
- Sponsors Blade Therapeutics
- 12 Oct 2021 New trial record
- 07 Oct 2021 According to a Blade Therapeutics media release, pending completion of the investigational new drug (IND) application process and subsequent regulatory activation of the IND the company plans to start phase 1 clinical study evaluating CNS-penetrant calpain inhibitor BLD-2184 in 1H-2022